Hyperphosphatemia - A Drug Pipeline Analysis Report by Technavio

Technavio has published a new report on the drug development pipeline for the treatment of hyperphosphatemia, including a detailed study of the pipeline molecules. (Photo: Business Wire)

LONDON--(BUSINESS WIRE)--Sep 11, 2018--Technavio has announced their latest drug pipeline analysis report on . The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of hyperphosphatemia. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180911005274/en/

Technavio has published a new report on the drug development pipeline for the treatment of hyperphosphatemia, including a detailed study of the pipeline molecules. (Photo: Business Wire)

Hyperphosphatemia: An overview

Hyperphosphatemia is a condition characterized by an electrolyte imbalance, which will result in a high level of serum phosphate concentration in the blood. Hyperphosphatemia is common in people with chronic kidney disease, especially in people with end-stage kidney disease. Hyperphosphatemia is also caused due to hypoparathyroidism, in which there will be low levels of parathyroid hormone (PTH).

There is an increased prevalence of cardiovascular diseases and mortality rates due to hyperphosphatemia. Hyperphosphatemia occurs due to the presence of abnormally high phosphate concentration in the blood and is prevalent in patients with reduced kidney functions.

This report is available at a USD 1,000 discount for a limited time only:

Hyperphosphatemia: Segmentation of pipeline molecules

Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. The preferred RoA is through oral mode as all molecules in the current pipeline are administered orally.

Between companies and institutions, companies led the drug development space for the treatment of hyperphosphatemia. Some of the key players include 3SBio, Ardelyx, and DAIICHI SANKYO.

Looking for more information?

Some of the key topics covered in the report include:

1.Scope of the Report

2.Regulatory Framework

3.Drug Development Landscape

Drugs under development

4.Drug Development Strategies

Therapies employedRoute of administrationTherapeutic modalityMechanism of action

5.Recruitment Strategies

Geographical coverageRecruitment statusGenderAge

6.Key Companies

Type of playersCompany overview

7. Discontinued and Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005274/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 09/11/2018 08:23 AM/DISC: 09/11/2018 08:23 AM

http://www.businesswire.com/news/home/20180911005274/en

Copyright Business Wire 2018.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.